Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients...
COPENHAGEN, Denmark--(BUSINESS WIRE)--Jun 11, 2022--
COPENHAGEN, Denmark--(BUSINESS WIRE)--Jun 11, 2022--